Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence in Situ Hybridization/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry

Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1,494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and outcomes were inferior for patients with unfavorable-risk disease. This highlights the importance of prognostic testing for patients with CLL to guide treatment and improve outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

ConclusionThe results of the present study have shown that for patients with CLL, the Binet clinical stages are good outcome predictors throughout the disease course and also suggest that changes in Binet clinical stage could be useful as response surrogates and to divide the IWCLL PR category into different prognostic subgroups.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Erin Bange, Colleen Timlin, Charlene Kabel, Jakub Svoboda, Lindsey Roeker, Anthony R. MatoAbstractComplementary and alternative medicine (CAM) is a diverse group of medical and health care systems, practices, and products that are not generally considered part of conventional medicine. Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in the western hemisphere, and 16.5% to 66% of patients have reported using CAM. Most patients use spiritual/mind–body techniques and high doses of vitamins and...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 June 2018Source: The Lancet HaematologyAuthor(s): Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier MahonSummaryTremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have inc...
Source: The Lancet Haematology - Category: Hematology Source Type: research
ConclusionThese results from an integrated analysis support a favorable benefit-risk profile of ibrutinib in patients with CLL/SLL and MCL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Erin Bange, Colleen Timlin, Charlene Kabel, Jakub Svoboda, Lindsey Roeker, Anthony R. MatoAbstractComplementary and alternative medicine (CAM) is a diverse group of medical and health care systems, practices, and products that are not generally considered part of conventional medicine1. Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in the western hemisphere2 and 16.5-66% of patients report using CAM. The majority of patients use spiritual/mind-body techniques as well as high doses of vitamins a...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Pilar Nava-ParadaAbstractCombination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies; however, the available comparative clinical evidence is limited. The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell l...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - Category: Hematology Authors: Source Type: research
Publication date: Available online 18 June 2018Source: The Lancet HaematologyAuthor(s): Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier MahonSummaryTremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have inc...
Source: The Lancet Haematology - Category: Hematology Source Type: research
ConclusionThese results from an integrated analysis support a favorable benefit-risk profile of ibrutinib in patients with CLL/SLL and MCL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Study